O-1238

O-1238
(IUPAC) ime
	(6aR)-3-[(Z)-6-azidoheks-2-enil]-6,6,9-trimetil-6a,7,10,10a-tetrahidrobenzo[c]hromen-1-ol
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	10761489
Hemijski podaci
Formula	C22H29N3O2
Mol. masa	367,483 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C22H30N3O2/c1-15-9-10-18-17(12-15)21-19(26)13-16(14-20(21)27-22(18,2)3)8-6-4-5-7-11-24-25-23/h4,6,9,13-14,17-18,23,26H,5,7-8,10-12H2,1-3H3 ; Key: HYCUZVYUXQYXFH-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

O-1238 je lek koji je kanabinoidni derivat. On se koristi u naučnim istraživanjima. O-1238 je parcijalni agonist kanabinoidnog receptora CB₁,^[3] sa maksimalnom stimulacijom od 58.3%^[4] i Ki vrednošću od 8,45 nM.^[5]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Griffin G, Wray EJ, Martin BR, Abood ME. Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum. British Journal of Pharmacology. 1999 Oct;128(3):684-8. DOI:10.1038/sj.bjp.0702806 PMID 10516649
↑ -[Griffin G, Wray EJ, Rorrer WK, Crocker PJ, Ryan WJ, Saha B, Razdan RK, Martin BR, Abood ME. An investigation into the structural determinants of cannabinoid receptor ligand efficacy. British Journal of Pharmacology. 1999 Apr;126(7):1575-84. DOI:10.1038/sj.bjp.0702469 PMID 10323589
↑ Ross RA, Gibson TM, Stevenson LA, Saha B, Crocker P, Razdan RK, Pertwee RG. Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. British Journal of Pharmacology. 1999 Oct;128(3):735-43. PMID 10516656

Vanjske veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Griffin G, Wray EJ, Martin BR, Abood ME. Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum. British Journal of Pharmacology. 1999 Oct;128(3):684-8. DOI:10.1038/sj.bjp.0702806 PMID 10516649

[4] -[Griffin G, Wray EJ, Rorrer WK, Crocker PJ, Ryan WJ, Saha B, Razdan RK, Martin BR, Abood ME. An investigation into the structural determinants of cannabinoid receptor ligand efficacy. British Journal of Pharmacology. 1999 Apr;126(7):1575-84. DOI:10.1038/sj.bjp.0702469 PMID 10323589

[5] Ross RA, Gibson TM, Stevenson LA, Saha B, Crocker P, Razdan RK, Pertwee RG. Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. British Journal of Pharmacology. 1999 Oct;128(3):735-43. PMID 10516656

[1]

[2]

[3]

[4]

[5]